Document is current
Any future updates will be listed below
-
Authors
Meguro, Satoru https://orcid.org/0000-0003-2179-5028
Johmura, Yoshikazu https://orcid.org/0000-0002-6812-9607
Wang, Teh-Wei
Kawakami, Satoshi
Tanimoto, Shota
Omori, Satotaka
Okamura, Yuki T.
Hoshi, Seiji
Kayama, Emina
Yamaguchi, Kiyoshi
Hatakeyama, Seira
Yamazaki, Satoshi https://orcid.org/0000-0003-4249-3854
Shimizu, Eigo
Imoto, Seiya
Furukawa, Yoichi https://orcid.org/0000-0003-0462-8631
Kojima, Yoshiyuki https://orcid.org/0000-0001-8000-0868
Nakanishi, Makoto https://orcid.org/0000-0002-6707-3584
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP23zf0127003h)
Japan Agency for Medical Research and Development (JP23gm1410013h)
Japan Agency for Medical Research and Development (JP20gm5010001s)
Japan Agency for Medical Research and Development (JP20ck010655h)
Japan Agency for Medical Research and Development (JP21gm6410014h)
MEXT | Japan Society for the Promotion of Science (JP20H00514)
MEXT | Japan Society for the Promotion of Science (JP20K21497)
MEXT | Japan Society for the Promotion of Science (JP19H05740)
MEXT | Japan Society for the Promotion of Science (JP19H03431)
MEXT | Japan Society for the Promotion of Science (JP20H04940)
- License Information
-
More Information
Article History
Received: 25 July 2023
Accepted: 8 August 2024
First Online: 9 September 2024
Competing interests
: M.N. is a scientific advisor and shareholder at reverSASP Therapeutics. S.Y. is a co-founder of Celaid Therapeutics. The other authors declare no competing interests.
